Key Takeaways:
Powered by lumidawealth.com
- Lipoprotein(a), a genetic cholesterol variant untreatable by statins, increases the risk of heart attacks and strokes by 2-3 times for 1-2 billion people worldwide.
- Eli Lilly’s experimental drug, lepodisiran, reduced lipoprotein(a) levels by 94% for six months in a Phase 2 trial, with Phase 3 trials now underway.
- Amgen’s olpasiran achieved a 97% reduction in lipoprotein(a) in Phase 2 trials, while Novartis’ pelacarsen reduced levels by 80% and is expected to report Phase 3 results this year.
- These drugs use RNA-based technologies, such as siRNA, to block liver cells from producing lipoprotein(a), offering a long-acting solution for this genetic condition.
What Happened?
Pharmaceutical giants Eli Lilly, Amgen, and Novartis are racing to develop groundbreaking treatments for lipoprotein(a), a genetic cholesterol variant that cannot be managed through diet, exercise, or existing drugs like statins.
Lilly’s lepodisiran and Amgen’s olpasiran, both using small interfering RNA (siRNA) technology, have shown remarkable efficacy in Phase 2 trials, reducing lipoprotein(a) levels by over 90%. Novartis’ pelacarsen, developed in partnership with Ionis Pharmaceuticals, is slightly less potent but is ahead in the race, with Phase 3 results expected this year.
These drugs work by targeting the RNA messages that instruct liver cells to produce lipoprotein(a), offering a long-acting solution with minimal side effects reported so far.
Why It Matters?
Lipoprotein(a) is a major risk factor for cardiovascular disease, distinct from LDL cholesterol, and affects up to a quarter of the global population. Until now, there have been no effective treatments for this genetic condition, leaving millions at elevated risk of heart attacks and strokes.
The success of these drugs could open a massive market for pharmaceutical companies while providing life-changing solutions for patients. However, the ultimate test will be whether these treatments can demonstrate a reduction in heart attacks and strokes in ongoing Phase 3 trials.
What’s Next?
Novartis is expected to lead the pack with Phase 3 results for pelacarsen later this year, while Amgen and Lilly’s drugs will require several more years of testing. If successful, these treatments could revolutionize cardiovascular care and provide relief for millions of patients with high lipoprotein(a).
Investors and healthcare professionals will be closely monitoring the outcomes of these trials, as well as the potential for regulatory approvals and market adoption. The competition among Big Pharma players underscores the high stakes and transformative potential of these therapies.
